로딩 중…
지수 로딩 중…
Neurogene Inc.
NGNE· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$32.87-0.06%
2026-08-03
Financials
Valuation Metrics
Neurogene Inc.'s Market Cap is $519M. At end of 2025 it was $436M. Ranked #2786 of 3,112 in US market (top 90%), #1209 of 1,445 on NASDAQ (top 84%), #223 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 83%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $519M | US#2,786/3,112 Sec#223/269 |
| Revenue | $0.00 | US#2,974/3,112 Sec#204/269 |
| Net Income | $-99M | US—/3,112 Sec—/269 |
| Total Assets | $263M | US#2,934/3,112 Sec#230/269 |
| Net Assets | $238M | US#2,664/3,112 Sec#181/269 |
| Value | ||
| P/B | 2.18x | US#1,295/3,112 Sec#57/269 |
| FCF Yield | -15.90% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -41.48% | US#2,702/3,112 Sec#156/269 |
| ROA | -37.48% | US#2,916/3,112 Sec#185/269 |
| Revenue Growth | -100.00% | US#2,948/3,112 Sec#190/269 |
| Financial Health | ||
| Debt Ratio | 10.66% | US#121/3,112 Sec#53/269 |
| Total Debt | $9M | US#2,792/3,112 Sec#201/269 |
| FCF | $-83M | US#2,551/3,112 Sec#139/269 |
| Cash | $124M | US#2,074/3,112 Sec#163/269 |
| Current Ratio | 13.08x | US#187/3,112 Sec#64/269 |
| Performance | ||
| 1Y Return | 50.92% | US#733/3,112 Sec#120/269 |
| 1M Return | -6.99% | US#2,415/3,112 Sec#142/269 |
| From 52W High | -24.71% | US#1,927/3,112 Sec#136/269 |
| 1Y MDD | -52.37% | US#2,495/3,112 Sec#192/269 |
| Trading | ||
| Volume | 154,796 shares | US#2,780/3,112 Sec#256/269 |
| Trading Value | $5M | US#2,664/3,112 Sec#220/269 |
| Per Share | ||
| EPS | $-3.10 | US—/3,112 Sec—/269 |
| BPS | $12.54 | US#1,620/3,112 Sec#53/269 |